Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUWILOID vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension (mild to moderate),Psychiatric disorders (e.g., schizophrenia, anxiety) – historically used
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.
250 mg orally twice daily
Terminal elimination half-life is approximately 10–12 hours. Clinical context: Requires twice-daily dosing for sustained antihypertensive effect; steady-state achieved in 2–3 days.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Primarily hepatic via cytochrome P450 enzymes (CYP2D6 and CYP3A4); undergoes extensive first-pass metabolism.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal excretion of metabolites; ~60–80% of a dose is eliminated in urine as metabolites, with <1% as unchanged drug. Biliary/fecal excretion accounts for ~15%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 90% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 1.6 L/kg. Clinical meaning: Indicates extensive tissue distribution beyond plasma volume; consistent with peripheral binding and accumulation in tissues.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: Approximately 30–50% due to first-pass metabolism.
70-90% (oral); 100% (IV).
Not recommended in patients with GFR <30 m L/min; for GFR 30-60 m L/min, reduce dose by 50%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use is contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for pediatric use; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at 1 mg orally once daily; increase slowly with close monitoring of blood pressure.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause depression (including suicidal ideation), bradycardia, orthostatic hypotension, nasal congestion, and gastrointestinal disturbances. Use with caution in patients with history of depression, peptic ulcer disease, or colitis. Avoid abrupt discontinuation to prevent rebound hypertension.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to rauwolfia alkaloids, history of depression (especially with suicidal tendencies), active peptic ulcer disease, ulcerative colitis, pheochromocytoma, and concurrent use with MAO inhibitors.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented products) as Rauwiloid may potentiate pressor effects; limit sodium intake to enhance antihypertensive effect; avoid large amounts of caffeine.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trimesters: may cause fetal bradycardia, hypotension, and hypothermia if used near term. Avoid use in pregnancy unless clearly needed.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Not known whether alseroxylon is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug. M/P ratio not available.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect drug levels; however, due to limited data, dose should be individualized and titrated to clinical response.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Rauwiloid (alseroxylon) is a rauwolfia alkaloid used for mild to moderate hypertension; its antihypertensive effect is due to depletion of catecholamines from peripheral sympathetic nerve endings; onset is slow (weeks) and prolonged; common side effects include nasal congestion, bradycardia, and depression; avoid in patients with history of depression or peptic ulcer disease; may cause sodium and water retention; taper dose to avoid rebound hypertension.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed; do not stop suddenly as this may cause a rapid increase in blood pressure.,Avoid alcohol and other central nervous system depressants as they can worsen drowsiness or dizziness.,You may experience nasal congestion, dry mouth, or slowed heart rate; report any signs of depression or mood changes.,Rise slowly from sitting or lying positions to prevent dizziness or fainting.,This medication may take several weeks to achieve full effect; continue taking it even if you feel well.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUWILOID vs ALDOCLOR-250, answered by our medical review team.
RAUWILOID is a Antihypertensive that works by Rauwiloid (alseroxylon) is a rauwolfia alkaloid that depletes catecholamines and serotonin from postganglionic sympathetic nerve endings and the central nervous system by inhibiting vesicular monoamine transporter (VMAT). This leads to reduced peripheral vascular resistance and decreased sympathetic outflow, resulting in antihypertensive and antipsychotic effects.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUWILOID and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUWILOID is: 2 mg orally twice daily, adjusted based on response; maximum 4 mg twice daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUWILOID and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUWILOID is classified as Category C. No adequate studies in pregnant women. Animal reproduction studies have not been conducted with Rauwiloid (alseroxylon). Use in first trimester: unknown risk. Second and third trim. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.